Ranimustine
Jump to navigation
Jump to search
Template:Short description Template:Cs1 config Template:Drugbox
Ranimustine (INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia[1] and polycythemia vera.[2]
It has never been filed for FDA evaluation in the United States, where it is not marketed.
Synthesis
Ranimustine is made by reacting the primary amine of a pyranose sugar (2) with o-nitrophenyl N-(2-chloroethyl)-N-nitrosocarbamate (1) to form the nitrosourea group.[3] [4]
References
<templatestyles src="Reflist/styles.css" />
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ <templatestyles src="Citation/styles.css"/>Template:Citation/make link, Goro Kimura, "Process for producing glucopyranose-nitrosourea compounds and novel compounds included therein", issued Script error: No such module "auto date formatter"., assigned to Tokyo Tanabe Co LtdScript error: No such module "Check for unknown parameters".
- ↑ Script error: No such module "Citation/CS1".
Script error: No such module "Check for unknown parameters".
External links
- Template:In lang Cymerin サイメリン (PDF) Mitsubishi Tanabe Pharma. October 2007.
Script error: No such module "Navbox".